| OR | 95% CI | p value* |
---|---|---|---|
Univariate analyses | |||
 Female | 0.845 | (0.373–1.915) | 0.687 |
 Age | 0.993 | (0.969–1.018) | 0.598 |
 Disease duration | 1.004 | (1.000–1.008) | 0.076 |
 CHB status | 3.129 | (1.661–5.895) | <0.001 |
 TJC28 | 0.996 | (0.934–1.063) | 0.914 |
 SJC28 | 0.982 | (0.908–1.062) | 0.651 |
 Pain VAS | 1.056 | (0.905–1.232) | 0.491 |
 PtGA | 1.094 | (0.939–1.274) | 0.248 |
 PrGA | 1.086 | (0.921–1.281) | 0.326 |
 HAQ | 1.346 | (0.990–1.830) | 0.058 |
 CRP | 1.001 | (0.998–1.014) | 0.876 |
 ESR | 0.999 | (0.989–1.008) | 0.786 |
 RF positivity | 2.355 | (0.921–6.023) | 0.074 |
 ACPA positivity | 1.983 | (0.775–5.070) | 0.153 |
 DAS28-CRP | 1.011 | (0.742–1.378) | 0.944 |
 MMP-3 | 1.001 | (0.999–1.002) | 0.292 |
 mTSS | 1.016 | (1.006–1.026) | 0.001 |
 Treatment-naïveb | 0.710 | (0.365–1.381) | 0.313 |
 GCs | 2.300 | (0.964–5.489) | 0.061 |
 MTX | 1.369 | (0.330–5.678) | 0.666 |
 LEF | 0.684 | (0.359–1.304) | 0.248 |
 SSZ | 1.984 | (0.876–4.495) | 0.101 |
 HCQ | 1.611 | (0.828–3.135) | 0.160 |
 CysA | 1.591 | (0.490–5.167) | 0.440 |
 Iguratimod | 1.130 | (0.348–3.670) | 0.839 |
 Biologic agents | 0.477 | (0.200–1.139) | 0.095 |
 MTX combined with SSZ and HCQ | 2.265 | (0.949–5.406) | 0.066 |
 MTX combined with LEF | 0.719 | (0.384–1.346) | 0.302 |
 One-year cumulative dose of GCsc | 1.000 | (1.000–1.000) | 0.010 |
 One-year cumulative dose of MTX | 0.999 | (0.998–1.000) | 0.224 |
 One-year cumulative dose of LEFd | 1.000 | (1.000–1.000) | 0.074 |
 One-year cumulative dose of SSZ | 1.001 | (1.000–1.003) | 0.133 |
 One-year cumulative dose of HCQ | 1.004 | (0.998–1.009) | 0.160 |
 One-year cumulative dose of CysAe | 1.000 | (1.000–1.000) | 0.124 |
 One-year cumulative dose of iguratimodf | 1.000 | (1.000–1.000) | 0.761 |
 One-year cumulative dose of tocilizumabg | 1.000 | (0.999–1.000) | 0.232 |
 One-year cumulative dose of Yi Sai Pu | 1.000 | (0.998–1.003) | 0.817 |
 One-year cumulative dose of infliximab | 0.997 | (0.989–1.006) | 0.564 |
Bivariate models | |||
 CHB status adjusted for baseline mTSS | 2.610 | (1.338–5.092) | 0.005 |
 CHB status adjusted for one-year cumulative dose of GCs | 2.881 | (1.511–5.493) | 0.001 |
Multivariate model | |||
 CHB status adjusted for baseline mTSS and one-year cumulative dose of GCs | 2.403 | (1.218–4.743) | 0.011 |